Ascletis Pharma (2VJ) Stock Overview
A biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
2VJ Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Ascletis Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.44 |
| 52 Week High | HK$1.96 |
| 52 Week Low | HK$0.46 |
| Beta | 0.50 |
| 1 Month Change | 11.63% |
| 3 Month Change | 48.45% |
| 1 Year Change | 206.38% |
| 3 Year Change | 185.15% |
| 5 Year Change | 400.00% |
| Change since IPO | 25.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2VJ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.4% | -2.4% | -1.4% |
| 1Y | 206.4% | -11.2% | 10.0% |
Return vs Industry: 2VJ exceeded the German Biotechs industry which returned -11.7% over the past year.
Return vs Market: 2VJ exceeded the German Market which returned 8.9% over the past year.
Price Volatility
| 2VJ volatility | |
|---|---|
| 2VJ Average Weekly Movement | 13.3% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 2VJ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2VJ's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 208 | Jinzi Jason Wu | www.ascletis.com |
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis.
Ascletis Pharma Inc. Fundamentals Summary
| 2VJ fundamental statistics | |
|---|---|
| Market cap | €1.44b |
| Earnings (TTM) | -€31.56m |
| Revenue (TTM) | €288.53k |
Is 2VJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2VJ income statement (TTM) | |
|---|---|
| Revenue | CN¥2.36m |
| Cost of Revenue | CN¥1.51m |
| Gross Profit | CN¥856.00k |
| Other Expenses | CN¥259.43m |
| Earnings | -CN¥258.57m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.26 |
| Gross Margin | 36.21% |
| Net Profit Margin | -10,937.78% |
| Debt/Equity Ratio | 0% |
How did 2VJ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/22 08:52 |
| End of Day Share Price | 2026/01/22 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ascletis Pharma Inc. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ling Zhang | China Merchants Securities (HK) Co., Ltd |
| Wangbin Zhou | Citigroup Inc |
| Ming Jiang | East Asia Qianhai Securities Co., Ltd |